Direkt zum Inhalt
Merck

M4659

Sigma-Aldrich

Milrinon

≥97% (TLC), powder, phosphodiesterase type III inhibitor

Synonym(e):

1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridin)-5-carbonitril

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C12H9N3O
CAS-Nummer:
Molekulargewicht:
211.22
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
41106305
PubChem Substanz-ID:
NACRES:
NA.77

Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Produktbezeichnung

Milrinon, ≥97% (TLC), powder

Qualitätsniveau

Assay

≥97% (TLC)

Form

powder

Farbe

off-white

Löslichkeit

DMSO: >10 mg/mL
H2O: insoluble

Ersteller

Sanofi Aventis

Lagertemp.

2-8°C

SMILES String

CC1=C(C=C(C#N)C(=O)N1)c2ccncc2

InChI

1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
PHR2515SML1184SML1209
Milrinon ≥97% (TLC), powder

M4659

Milrinon

Milrinon Pharmaceutical Secondary Standard; Certified Reference Material

PHR2515

Milrinon

OF-1 ≥98% (HPLC)

SML1184

OF-1

OICR-9429 ≥98% (HPLC)

SML1209

OICR-9429

assay

≥97% (TLC)

assay

-

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

200

Quality Level

300

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: >10 mg/mL, H2O: insoluble

solubility

-

solubility

DMSO: 5 mg/mL, clear (warmed)

solubility

DMSO: 10 mg/mL, clear

color

off-white

color

-

color

white to beige

color

white to light brown

Biochem./physiol. Wirkung

Phosphodiesterase type III inhibitor; cAMP-specific, cGMP-inhibitable; potent cardiotonic, positive inotropic vasodilator.

Leistungsmerkmale und Vorteile

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Skull and crossbones

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Acute Tox. 3 Oral

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Dirk Bassler et al.
The Cochrane database of systematic reviews, (11)(11), CD007802-CD007802 (2010-11-12)
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical syndrome characterized by suboptimal oxygenation as a result of sustained elevation in pulmonary vascular resistance after birth. Currently, the therapeutic mainstay for PPHN is optimal lung inflation and selective vasodilatation
Baozeng Xu et al.
Developmental biology, 385(2), 242-252 (2013-11-20)
The oocyte becomes competent for embryonic development by involving mutual communication with cumulus cells (CCs) during folliculogenesis. How this communication takes place under physiological conditions is not fully understood. Current study examined oocyte-CCs communication in the XY sex-revered female mouse.
R Krams et al.
American heart journal, 121(6 Pt 2), 1951-1955 (1991-06-01)
Bipyridine derivatives have recently been introduced as a new class of inodilator drugs in the intravenous therapy of heart failure. A member of this class is milrinone, which improves the inotropic state and reduces ventricular afterload, leading to improved hemodynamics.
Maria Otilia Bianchi et al.
Shock (Augusta, Ga.), 44(2), 115-120 (2015-04-22)
Despite the advancement in the postoperative care of neonates with congenital heart disease (CHD), there is little information on preoperative management of systemic and regional hemodynamics, which may be related to outcomes. We aimed to determine the preoperative effect of
Jerrold H Levy et al.
The Annals of thoracic surgery, 73(1), 325-330 (2002-02-09)
Phosphodiesterase inhibitors including milrinone produce positive inotropic effects by slowing the hydrolysis of cyclic adenosine monophosphate in the myocardium. With a loading dose of 50 microg/kg followed by an infusion of 0.5 microg x kg(-1) x min(-1), milrinone increases stroke

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.